{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:36Z","timestamp":1782031716100,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.10.019","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:50:34Z","timestamp":1776347434000},"page":"11-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Dess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget F.","family":"Koontz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.10.019_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0002","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0003","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0004","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41391-024-00862-8","article-title":"The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer","volume":"28","author":"Le Guevelou","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer","volume":"4","author":"Deek","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0007","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0008","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41391-025-00950-3","article-title":"Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)","volume":"28","author":"Francolini","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0009","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111041","article-title":"The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial","volume":"210","author":"Ruicci","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0011","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijrobp.2024.09.002","article-title":"The Role of stereotactic body radiotherapy in oligoprogressive malignant disease (RADIANT): oncologic outcomes from a phase 2 nonrandomized controlled trial","volume":"121","author":"Glicksman","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijrobp.2025.02.046","article-title":"Stereotactic body radiation therapy for oligoprogressive disease in androgen-suppressed prostate cancer: primary endpoint analysis of the TRAP trial","volume":"125","author":"Patel","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.10.019_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162506403X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162506403X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:32:24Z","timestamp":1782030744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162506403X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S036030162506403X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.10.019","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}